SAN2219
Not Specified (CNS/Rare Disease)
Preclinical/Phase 1Active
Key Facts
About Saniona
Saniona is a Danish biotech pioneer with a core competency in ion channel modulation, a historically challenging drug target class. The company has built a robust discovery engine and a library of over 20,000 proprietary molecules, translating this platform into a clinical-stage pipeline focused on epilepsy and rare CNS disorders. A recent licensing agreement with Jazz Pharmaceuticals validates its approach and provides non-dilutive funding. The company's strategy is to advance its own programs while leveraging partnerships to maximize the value of its ion channel platform.
View full company profile